Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Becton Dickinson wins reversal of $340 million syringe award

Published 12/02/2016, 02:20 PM
Updated 12/02/2016, 02:30 PM
Becton Dickinson wins reversal of $340 million syringe award

By Jonathan Stempel

(Reuters) - A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co (N:BDX) to pay rival Retractable Technologies Inc (A:RVP) $340 million in damages over its marketing of safety syringes.

Shares of Retractable tumbled more than 50 percent and hit their lowest level in roughly 3-1/2 years.

The 5th U.S. Circuit Court of Appeals in New Orleans called Retractable's claim that Becton violated the Sherman Act by trying to monopolize the U.S. safety syringe market "infirm as a matter of law."

Writing for a 3-0 panel, Judge Edith Jones also called "unsupported and incoherent" the allegation that Becton "tainted" the market for retractable syringes while secretly plotting to offer its own once Retractable's patents expired.

"RTI has not demonstrated that BD engaged in predatory or anticompetitive conduct," Jones wrote.

But the appeals court agreed that Franklin Lakes, New Jersey-based Becton could be held liable for falsely advertising that its needles were sharper and wasted less medicine.

It ordered a lower court judge to decide how much profit Becton should give up as a result.

Safety syringes are designed to protect patients from needlestick injuries and contamination.

Both Retractable and Becton, and their law firms, did not immediately respond to requests for comment.

Shares of Retractable were down $1.26, or 51.4 percent, at $1.19 in afternoon trading, after earlier falling as low as $1.15. Becton shares were up 0.4 percent at $165.36.

Retractable, based in Little Elm, Texas, accused Becton of trying to thwart competition by offering loyalty discounts and rebates, or requiring that customers not buy syringes elsewhere.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In September 2013, a federal jury in Texas awarded Retractable roughly $113.5 million in damages, which was later tripled.

That verdict later became the basis for an injunction requiring Becton to tell customers about its false claims.

Jones voided that injunction, but said a substitute based on the false advertising violations was "theoretically possible."

The case is Retractable Technologies Inc et al v. Becton Dickinson & Co, 5th U.S. Circuit Court of Appeals, No. 14-41384.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.